

There may be hope..

hovid
Continuous Innovation & Quality



PREGAVID
Capsule 150 mg

PREGAVID
Capsule 75 mg



Pain away get it off your nerves

LIVING **WITH PAIN**

CAN BE **DEBILITATING¹**

The unhighlighted PAIN BURDEN

Chronic pain, usually defined as pain lasting for 3 months or more, is the leading cause of disability worldwide¹.

Up to **1 in 10** suffer from chronic **neuropathic** pain globally^(2,3)



9 in 100

of the population⁴ experienced chronic bodily pain
⁴ aged 13 years old and over

WHAT IS CHRONIC BODILY PAIN?

Pain in any parts of the body, which is felt every day or most days for 3 months or more


Who were effected?

1.6%



Teenagers aged 13-14

Pain prevalence increases with **increasing age**



29.3%



Elderly aged 75 years and over

What is **Neuropathic Pain**?

⁴ pain caused by a lesion or disease of the **somatosensory** nervous system²⁴

Neuropathic pain :

complex, chronic, severe challenging to treat and manage can impact quality of life limit mobility contribute to depression and social dysfunction.



BURNING

ALLODYNIA

ACHING

SHARP

DEEP


Management of **neuropathic pain**^{8,9}

- Medical assessment of causes of pain.
- Optimizing Tx of underlying cause for eg improving glycemic control and lifestyle interventions in diabetes.
- Assessment of baseline severity and optimizing pain reduction.
- Improvement of quality of life (eg sleep and mood disorders).
- Pharmacotherapy-Gabapentins including pregabalin as first line therapy.**


Pregabalin in pDN (peripheral diabetic neuropathy)

Pregabalin significantly provides rapid, sustained decrease in pain scores in pDN¹⁰

In 7 pooled RCTs in pDN, pregabalin was effective as early as Week 1 to significantly decrease pain scores¹¹



% patients responding to treatment with a $\geq 50\%$ decrease in baseline daily pain



Change from baseline to week 5 in least-squares mean pain score



Pregabalin improves quality of life in pDN

Pregabalin significantly improves sleep and quality of life in terms of reduction of pain in pDN^{10,11,12}

Pregabalin 300 mg/day and 600 mg/day significantly improved patients' impression of pain¹⁰


Patients receiving 600 mg/day pregabalin had significantly lower sleep interference scores starting at week 1 and at end point¹⁰

Pregabalin 600 mg/day vs placebo comparison significant, P=0.002, using the CMH test




Pregabalin significantly reduces pain in patients with Low Back Pain with a neuropathic component.¹³

Pregabalin 300 to 600 mg daily significantly reduces pain in about 1 in 10 people with moderate or severe pain from fibromyalgia.



Pregabalin(PGB) vs Placebo(PCB)
Outcome: At least 50% pain relief –substantial pain relief (% Percentage patients with Outcome)




Efficacy for treatment of pain assessed using pain numerical rating scale (NRS)
Adapted from Derry S, et al Cochrane Database Syst Rev. 2016

Pregabalin in Post herpetic neuralgia (PHN)


Persistent Pain in Over Half of Shingles Patients

PHN occurs in more than 50% of patients with herpes zoster characterized by persistent (≥3 months) lancinating/burning pain, & paraesthesia or near the area of rash.¹⁶



Pregabalin Effective for Neuropathic Pain in PHN18

Pregabalin is highly effective and well-tolerated for the treatment of neuropathic pain in PHN18



Age-Related Increase in Postherpetic Neuralgia (PHN)


58 years old lady with diabetes and normal kidney function. She had chicken pox as a child.



After 1 month.....



Pregabalin in Post herpetic neuralgia (PHN)



Pregabalin is proven bioequivalent to innovator¹⁹

PK Parameters (units)	Acceptance BE Range	90% confidence interval	Result
C_{max} (ng/ml)	80.00%-125.00%	92.25 - 101.87	Bioequivalent
AUC_{0-1} (ng.h/ml)	80.00%-125.00%	96.77 - 104.52	Bioequivalent

SAFETY AND PRECAUTION

If pregabalin has to be discontinued, it is recommended to taper over a minimum of 1 week. Dosage reduction in patients with renal impairment & the elderly. Common side effects include dizziness & somnolence—advice to avoid driving & operating machinery.

* Refer to Full prescribing information for Precautions, Special Precautions and Contraindications²

REFERENCE 1

1. Basavane G et al. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. Pain Rep. 2023 Mar;9(2):v1066.
2. Scholz J et al. Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019 Jan;160(1):53-59.
3. Sook D et al. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol. 2019 Nov 21;2019:8685954.
4. Institute for Public Health 2020. National Health and Morbidity Survey (NHMS) 2019: Non-communicable diseases, healthcare demand, and health literacy—Key Findings.
5. Institute for Public Health 2024. National Health and Morbidity Survey (NHMS) 2023: Non-communicable Diseases and Healthcare Demand - Key Findings.
6. Ministry of Health Malaysia. Clinical Practice Guidelines Management of Neuropathic Pain (Second Edition) 2022.
7. MSD Manual: Neuropathic Pain 2022. Available at: <https://www.msdmanuals.com/en-sg/professional/neurologic-disorders/pain/neuropathic-pain>. Accessed 29.05.24.
8. Price R et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Report of the AAN Guideline Subcommittee. Neurology. 2022 Jan 4;98(1):33-43.
9. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024. Diabetes Care. 1 January 2024; 47 (Supplement 1): S231-S243.
10. Richter RW et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005 Apr;6(4):253-60.
11. Freeman R et al. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul;31(7):1448-54.
12. Hovid Pregabalin Full Prescribing Information 2024.
13. Taguchi T et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J Pain Res. 2015 Aug 5;8:487-97. doi: 10.2147/JPR.S88642. PMID: 26346468. PMCID: PMC4331006.
14. Shargawa J, Hurley JA. Fibromyalgia. [Updated 2023 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK540974/>. Accessed 31.05.24.
15. Derry S et al. Pregabalin for pain in Fibromyalgia in adults. Cochrane Database Syst Rev. 2016 Sep 29;9(9):CD010790.
16. Gruer C, Cuthmillier KB. Postherpetic Neuralgia. [Updated 2023 Apr 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK63998/>. Accessed 03.06.24.
17. Cao X et al. A Meta-analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Pregabalin and Gabapentin in the Treatment of Postherpetic Neuralgia. Pain Ther. 2023 Feb;3(1):1-18.
18. Stacey BR et al. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008 Nov;9(11):1006-17. doi: 10.1016/j.pain.2008.05.014. Epub 2008 Jul 18. PMID: 18640074.
19. Pregabalin bioequivalence study. Data on file. Hovid Berhad.

For Healthcare Professional Only.



Scan the QR code for Pregabalin Full Prescribing Information



For more information:

Hovid Pharmacy Sdn Bhd
C-06-3A & 5, Block C, Oasis Square, 2A Jalan PJU 1A/7A,
Ara Damansara, 47301 Petaling Jaya, Selangor, Malaysia.
+60(3) 7831 2738 | customercare@hovid.com

hovid